Michigan Progressive Health Market Research Report

Background

Overview

Michigan Progressive Health (MPH) is a physician-led clinic specializing in ketamine-assisted psychotherapy, aiming to improve the lives of individuals dealing with depression, anxiety, PTSD, and chronic pain. Established in 2016, MPH operates two locations in Michigan: Royal Oak and Ann Arbor. The clinic offers innovative treatments, including SPRAVATO® (esketamine), and collaborates with insurance providers such as Blue Cross Blue Shield PPO and Aetna, as well as offering self-pay options.

Mission and Vision

MPH is dedicated to providing integrative ketamine treatments that enhance patient well-being. The clinic's mission is to offer compassionate care, utilizing ketamine therapy to help patients achieve mental wellness and overcome chronic conditions. Their vision is to be a leading center for ketamine-assisted psychotherapy, fostering breakthroughs that lead patients closer to mental health.

Industry Significance

As a pioneer in ketamine-assisted psychotherapy in Michigan, MPH plays a crucial role in expanding treatment options for mental health conditions. The clinic's innovative approach contributes to the growing acceptance and integration of alternative therapies in mainstream mental health care.

Key Strategic Focus

Core Objectives

Innovative Treatment Delivery: Provide cutting-edge ketamine-assisted psychotherapy to address mental health challenges.

Patient-Centered Care: Ensure compassionate and personalized treatment plans for each patient.

Community Engagement: Raise awareness and educate the community about the benefits of ketamine therapy.

Areas of Specialization

Ketamine-Assisted Psychotherapy: Specializing in the integration of ketamine therapy with psychotherapy to treat mood disorders and chronic pain.

Mental Health Conditions: Addressing depression, anxiety, PTSD, and chronic pain through innovative treatments.

Key Technologies Utilized

SPRAVATO® (Esketamine): A nasal spray approved for treatment-resistant depression, offering rapid relief of depressive symptoms.

Ketamine Infusion Therapy: Administering ketamine intravenously to facilitate neuroplasticity and alleviate mental health symptoms.

Primary Markets Targeted

Geographic Focus: Serving residents in the Royal Oak and Ann Arbor areas of Michigan.

Demographic Focus: Individuals experiencing treatment-resistant mental health conditions and chronic pain.

Financials and Funding

Funding History

Specific details regarding MPH's funding history, total funds raised, recent funding rounds, and notable investors are not publicly disclosed.

Utilization of Capital

While exact allocations are not specified, it is reasonable to infer that capital has been directed towards:

Facility Expansion: Establishing and maintaining treatment centers in Royal Oak and Ann Arbor.

Technology Acquisition: Investing in advanced medical equipment and treatment technologies.

Staff Development: Recruiting and training qualified medical and therapeutic personnel.

Pipeline Development

Key Pipeline Candidates

MPH focuses on the integration of ketamine therapy with psychotherapy, utilizing SPRAVATO® (esketamine) as a primary treatment modality. The clinic is continually assessing and incorporating emerging research to enhance treatment efficacy.

Stages of Clinical Trials or Product Development

As a clinical service provider, MPH does not engage in the development of pharmaceutical products but applies existing treatments in a clinical setting.

Target Conditions

Depression: Including treatment-resistant depression.

Anxiety Disorders: Addressing various anxiety-related conditions.

Post-Traumatic Stress Disorder (PTSD): Providing therapeutic interventions for PTSD.

Chronic Pain: Offering pain management solutions through innovative therapies.

Anticipated Milestones

Expansion of Services: Potential introduction of additional therapeutic modalities.

Research Initiatives: Engagement in studies to further validate treatment approaches.

Community Outreach: Increased educational programs to raise awareness about ketamine therapy.

Technological Platform and Innovation

Proprietary Technologies

MPH utilizes SPRAVATO® (esketamine), a proprietary nasal spray developed by Janssen Pharmaceuticals, as a key component of its treatment offerings.

Significant Scientific Methods

Ketamine-Assisted Psychotherapy: Combining ketamine administration with psychotherapy to facilitate breakthroughs in mental health treatment.

Neuroplasticity Enhancement: Leveraging ketamine's ability to promote neural growth and connectivity, aiding in the treatment of mood disorders.

Leadership Team

Dr. Megan Oxley, Medical Director

Professional Background: Board-certified Emergency Medicine physician with a fellowship in Integrative Psychiatry.

Contributions: Founded MPH in 2016 to provide innovative ketamine treatments, serving as a leading figure in ketamine-assisted psychotherapy.

Dr. Kathryn Chilton, Psychiatrist

Professional Background: Medical degree from the University of Michigan, psychiatry residency at the University of Wisconsin, with experience in psilocybin studies and ketamine-assisted psychotherapy.

Contributions: Developed a Ketamine-Assisted Psychotherapy program at the Wisconsin Department of Veterans Affairs and co-authored a KAP protocol implemented in multiple VA facilities.

Lauren Harrison, LMSW, Ketamine Therapist

Professional Background: Master of Social Work from the University of Michigan, trained in ketamine-assisted psychotherapy.

Contributions: Provides therapy integrating ketamine treatment, focusing on creating a safe space for clients to explore and heal.

Nate Robertson, LMSW, Therapist

Professional Background: Clinical social worker with a Master of Social Work from the University of Michigan, trained in ketamine-assisted psychotherapy.

Contributions: Specializes in integrating ketamine therapy with psychotherapy to address mental health challenges.

Jordo Ceresnie, LLPC, Therapist

Professional Background: Master's degree in Mindfulness-Based Transpersonal Counseling from Naropa University, trained in ketamine-assisted psychotherapy.

Contributions: Supports clients in accessing their inner wisdom and transformation through ketamine-assisted therapy.

Rosie, Intake Coordinator / Office Manager

Professional Background: Experience in private-duty nursing and clinical care coordination at Michigan Medicine.

Contributions: Ensures efficient office operations and exceptional customer service, supporting the clinic's mission.

Competitor Profile

Market Insights and Dynamics

The mental health treatment market in Michigan is evolving, with increasing acceptance of alternative therapies like ketamine-assisted psychotherapy. MPH faces competition from traditional mental health providers and emerging clinics offering similar services.

Competitor Analysis

Traditional Mental Health Providers: Established clinics and hospitals offering conventional therapies.

Emerging Ketamine Clinics: New entrants providing ketamine-assisted treatments, contributing to a competitive landscape.

Strategic Collaborations and Partnerships

MPH collaborates with insurance providers such as Blue Cross Blue Shield PPO and Aetna, as well as offering self-pay options, to enhance accessibility for patients.

Operational Insights

MPH differentiates itself through its specialized focus on ketamine-assisted psychotherapy, offering a unique treatment modality not widely available in the region. The clinic's compassionate care approach and innovative treatment options position it as a leader in this niche market.

Strategic Opportunities and Future Directions